Cell Therapy Manufacturing Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2016-2026 Segmented By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell (Autologous v/s Allogenic), By Scale of Operation (Preclinical, Clinical, Commercial), By Source (In-House v/s Contract Manufacturing), By Applicatio
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationCell Therapy Manufacturing Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2016-2026 Segmented By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell (Autologous v/s Allogenic), By Scale of Operation (Preclinical, Clinical, Commercial), By Source (In-House v/s Contract Manufacturing), By Applicatio
Global Cell Therapy Manufacturing market stood at USD3123.44 million in 2020 and is expected to grow at a steady CAGR of 12.0% during the forecast period. The market growth can be attributed to advancing biopharmaceutical industries, all over the globe. The development of the advancing therapies and transforming paradigm of several life-threatening diseases is driving the growth of the global cell therapy manufacturing market in the upcoming five years. Apart of that growing prevalence of diseases such as cancer, cardiovascular diseases, diabetes, and others is expected to support the growth of the market.
Healthcare industry is involved in the extensive research and technological advancements that leads to the advanced medicine and treatment facilities for the patients. The urgent need for effective therapies as well as a vaccine against the infection supported the exponential growth in the market in the past two years. The market is expected to sustain similar growth in future five years on the same factor. Although the research is consistently growing, the expertise in the sector is limited and the lack of specialized infrastructure to produce cell therapies and various product development may cause a mild restraint on the future growth of the market.
Sudden Outbreak & Spread of COVID-19 Driving Market Growth
Sudden outbreak & spread of COVID-19 drives the growth of cell therapy manufacturing market. Due to COVID-19, a rapid increase in research and development of cell-based vaccines for the treatment of COVID-19 was observed. However, Novartis continued to supply raw materials for cell-based therapies. Many of the raw materials used to manufacture viral vector-based vaccines have been transferred to develop and manufacture what could be billions of doses of COVID-19 vaccines. several biotech organizations took the initiative to examine the virus’s genome to come up with a sustainable vaccine. For instance, in November 2020, Novartis obtained the license for the Mesoblast’s cell therapy Remestemcel-L for the treatment of COVID-19.
Growing Popularity of Regenerative Medicine
Regenerative medicine is still in its infancy, but patient demand and ease of use are growing among healthcare experts. Significant development and advancement in regenerative medicine
Rising Prevalence of Cancer, Cardiac and Other Ailments
There has been a tremendous rise in cardiac cases, cancer ailments, and other diseases since the past decade, resulting in the rising need for cell-based therapies. Many innovative approaches are being developed to repair damaged heart muscle using cell-based therapies. Human retinal pigment epithelium and photoreceptor cells are employed in retinal cell therapy programs for dry age-related macular degeneration (AMD) and inherited retinal diseases (IRDs), which are now in pre-clinical research. Hence, the rising prevalence of diseases contributes to the growth of the cell-based therapies market.
Rising Government Investments in Cell-Based Research
The presence of government and commercial funding agencies that are continually issuing grants to support projects at various phases of clinical trials can be ascribed to the growing number of ongoing clinical studies and the introduction of innovative solutions, boosting the cell therapy manufacturing market. The growing awareness pertaining to health and hygiene has led to an increase in expenditure by different governments across the globe to develop adequate healthcare infrastructure in their countries, leading to the growth and development of new innovative cell-based therapies by various companies and universities.
Click here to download the sample
Market Segmentation
The global Cell Therapy Manufacturing market is segmented based on
United States Cell Therapy Manufacturing Market expected to grow at a CAGR of 12.75% during the Forecast Period.
Company Profiles
Novartis AG
| Attribute | Details |
| Market Size Value in 2020 | USD 3123.44 Million |
| Revenue Forecast in 2026 | USD 6015.09 Million |
| United States Market Size value in 2020 | USD 870.94 Million |
| Growth Rate | 12.0% |
| Base Year | 2020 |
| Historical Years | 2016 – 2019 |
| Estimated Year | 2021 |
| Forecast Period | 2022 – 2026 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2016-2020 and 2021-2026 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regional Scope | North America; Europe; Asia Pacific; South America; Middle East & Africa |
| Country Scope | United States; Mexico; Canada; Germany; France; United Kingdom; Spain; Italy; China; Japan; South Korea; Australia; India; Brazil; Argentina; Colombia; Israel; South Africa; Saudi Arabia; UAE |
| Key Companies Profiled | Novartis AG, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Thermo Fischer Scientific, Inc., Catalent, Inc., JSR Life Sciences LLC (KBI Biopharma Inc), Waisman Center (Waisman Biomanufacturing), Cell and Gene Therapy Catapult, Merck KGaA, Lonza Group, Oxford Biomedica Plc, WuXi AppTec, Charles River Laboratories International Inc., Institut Merieux (ABL Inc.), BioCentriq, Centre for Commercialization of Regenerative Medicine (CCRM), Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics), Amgen Inc., Bluebird Bio Inc., Takeda Pharmaceutical Company Limited |
| Customization Scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/pdf format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy